Clinical TrialsThe acceleration in patient enrollment and dosing in the RESET trials for CABA-201 is encouraging, with the company positioned to begin dosing one patient a week for the next several months.
Market OpportunityThe potential for CABA-201 to capture more market share, particularly in women of childbearing age, could provide opportunity for growth.
Safety ProfileThe safety profile remains positive, with 90% of the first 10 patients dosed experiencing either no CRS or only grade 1 CRS.